BPDE treatment of lung cancer cells results in ATR/Chk1-mediated recruitment of Pol κ via Rad18 and the subsequent monoubiquitination of PCNA, and inhibition of ATR/Chk1 signaling prevents the interaction between Pol κ and PCNA [155]. The gene discussed is CHEK1; the disease is lung carcinoma.